![DPP4 Promotes Human Endothelial Cell Senescence and Dysfunction via the PAR2–COX-2–TP Axis and NLRP3 Inflammasome Activation | Hypertension DPP4 Promotes Human Endothelial Cell Senescence and Dysfunction via the PAR2–COX-2–TP Axis and NLRP3 Inflammasome Activation | Hypertension](https://www.ahajournals.org/cms/asset/9f5fe16a-cb9c-43a4-ad5b-21bf6c10d9c3/hypertensionaha.121.18477.fig07.jpg)
DPP4 Promotes Human Endothelial Cell Senescence and Dysfunction via the PAR2–COX-2–TP Axis and NLRP3 Inflammasome Activation | Hypertension
![Pharmaceuticals | Free Full-Text | Dipeptidyl Peptidase (DPP)-IV Inhibitors with Antioxidant Potential Isolated from Natural Sources: A Novel Approach for the Management of Diabetes Pharmaceuticals | Free Full-Text | Dipeptidyl Peptidase (DPP)-IV Inhibitors with Antioxidant Potential Isolated from Natural Sources: A Novel Approach for the Management of Diabetes](https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-14-00586/article_deploy/html/images/pharmaceuticals-14-00586-g001.png?1624331365)
Pharmaceuticals | Free Full-Text | Dipeptidyl Peptidase (DPP)-IV Inhibitors with Antioxidant Potential Isolated from Natural Sources: A Novel Approach for the Management of Diabetes
![Illustration of potential synergistic effects of SGLT2 inhibitor with... | Download Scientific Diagram Illustration of potential synergistic effects of SGLT2 inhibitor with... | Download Scientific Diagram](https://www.researchgate.net/publication/317028267/figure/fig3/AS:962851195846668@1606573022524/Illustration-of-potential-synergistic-effects-of-SGLT2-inhibitor-with-DPP-4-inhibitor-in.gif)
Illustration of potential synergistic effects of SGLT2 inhibitor with... | Download Scientific Diagram
![IJERPH | Free Full-Text | The Role of DPP-4 Inhibitors in the Treatment Algorithm of Type 2 Diabetes Mellitus: When to Select, What to Expect IJERPH | Free Full-Text | The Role of DPP-4 Inhibitors in the Treatment Algorithm of Type 2 Diabetes Mellitus: When to Select, What to Expect](https://www.mdpi.com/ijerph/ijerph-16-02720/article_deploy/html/images/ijerph-16-02720-sch001.png)
IJERPH | Free Full-Text | The Role of DPP-4 Inhibitors in the Treatment Algorithm of Type 2 Diabetes Mellitus: When to Select, What to Expect
![Soluble DPP4 induces inflammation and proliferation of human smooth muscle cells via protease-activated receptor 2 - ScienceDirect Soluble DPP4 induces inflammation and proliferation of human smooth muscle cells via protease-activated receptor 2 - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0925443914001690-fx1.jpg)
Soluble DPP4 induces inflammation and proliferation of human smooth muscle cells via protease-activated receptor 2 - ScienceDirect
![DPP4 degrade the GLP1 and incretion, which leads to suppression of the... | Download Scientific Diagram DPP4 degrade the GLP1 and incretion, which leads to suppression of the... | Download Scientific Diagram](https://www.researchgate.net/publication/343774145/figure/fig2/AS:926657976225795@1597943886841/DPP4-degrade-the-GLP1-and-incretion-which-leads-to-suppression-of-the-insulin.png)
DPP4 degrade the GLP1 and incretion, which leads to suppression of the... | Download Scientific Diagram
![GLP-1 receptor agonist versus DPP-4 inhibitor and kidney and cardiovascular outcomes in clinical practice in type-2 diabetes - ScienceDirect GLP-1 receptor agonist versus DPP-4 inhibitor and kidney and cardiovascular outcomes in clinical practice in type-2 diabetes - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0085253821010656-fx1.jpg)
GLP-1 receptor agonist versus DPP-4 inhibitor and kidney and cardiovascular outcomes in clinical practice in type-2 diabetes - ScienceDirect
![Frontiers | DPP4 and ACE2 in Diabetes and COVID-19: Therapeutic Targets for Cardiovascular Complications? Frontiers | DPP4 and ACE2 in Diabetes and COVID-19: Therapeutic Targets for Cardiovascular Complications?](https://www.frontiersin.org/files/MyHome%20Article%20Library/569989/569989_Thumb_400.jpg)
Frontiers | DPP4 and ACE2 in Diabetes and COVID-19: Therapeutic Targets for Cardiovascular Complications?
![DPP4/CD32b/NF-κB Circuit: A Novel Druggable Target for Inhibiting CRP-Driven Diabetic Nephropathy - ScienceDirect DPP4/CD32b/NF-κB Circuit: A Novel Druggable Target for Inhibiting CRP-Driven Diabetic Nephropathy - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1525001620304275-fx1.jpg)
DPP4/CD32b/NF-κB Circuit: A Novel Druggable Target for Inhibiting CRP-Driven Diabetic Nephropathy - ScienceDirect
![Dipeptidyl Peptidase-4 Inhibitor Increases Vascular Leakage in Retina through VE-cadherin Phosphorylation | Scientific Reports Dipeptidyl Peptidase-4 Inhibitor Increases Vascular Leakage in Retina through VE-cadherin Phosphorylation | Scientific Reports](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fsrep29393/MediaObjects/41598_2016_Article_BFsrep29393_Fig1_HTML.jpg)
Dipeptidyl Peptidase-4 Inhibitor Increases Vascular Leakage in Retina through VE-cadherin Phosphorylation | Scientific Reports
![Worsening Heart Failure During the Use of DPP-4 Inhibitors: Pathophysiological Mechanisms, Clinical Risks, and Potential Influence of Concomitant Antidiabetic Medications | JACC: Heart Failure Worsening Heart Failure During the Use of DPP-4 Inhibitors: Pathophysiological Mechanisms, Clinical Risks, and Potential Influence of Concomitant Antidiabetic Medications | JACC: Heart Failure](https://www.jacc.org/cms/asset/d8c3114d-201a-43e8-b42b-ac34be4f2119/fx1.jpg)
Worsening Heart Failure During the Use of DPP-4 Inhibitors: Pathophysiological Mechanisms, Clinical Risks, and Potential Influence of Concomitant Antidiabetic Medications | JACC: Heart Failure
![PDF] The effects of DPP-4 inhibitors on vascular endothelial function in diabetes | Semantic Scholar PDF] The effects of DPP-4 inhibitors on vascular endothelial function in diabetes | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/8fb6a87966c41c0daa40f827f9b144c9e29c9f08/79-Figure1.8-1.png)
PDF] The effects of DPP-4 inhibitors on vascular endothelial function in diabetes | Semantic Scholar
![Development of a treatment selection algorithm for SGLT2 and DPP-4 inhibitor therapies in people with type 2 diabetes: a retrospective cohort study - The Lancet Digital Health Development of a treatment selection algorithm for SGLT2 and DPP-4 inhibitor therapies in people with type 2 diabetes: a retrospective cohort study - The Lancet Digital Health](https://www.thelancet.com/cms/asset/86410633-66f9-484f-820c-0f6c5e3ab6b2/gr1.jpg)